摘要
尽管有关的发病机制和新的治疗策略的最新研究发现,在急性肾损伤(AKI)患者的死亡率仍然很高。有肾功能损害的早期检测的患者可能有助于确保更积极的治疗,提高临床疗效。血清肌酐仍然是肾损伤的金标准,虽然它被称为不敏感和不可靠的生物标志物(例如,它的浓度不增加显着,直到约一半的肾功能丢失)。考虑到这些数据,研究和临床医生都作出了巨大的努力,在过去的十年里,为了发现和验证新的AKI生物标志物。肾损伤分子-1(KIM-1)、中性粒细胞明胶酶蛋白(NGAL)、白细胞介素-18(IL-18)、Cystatin C(Cys-C)有一些新的肾损伤,目前在临床前和临床研究的重点有前途的标记。最近的数据表明,这些新的生物标志物,是急性肾小管坏死的重要参数(ATN)和预后的可靠预测AKI的发展。此外,这些标志物的监测可以早期诊断和临床过程有重要意义,不仅在各种形式的AKI和其他肾脏疾病的患者,而且患者心肾综合征、心力衰竭、心肺转流,心胸外科干预,在儿科急救设置等有作用。 这篇评论的目的是总结一些新的生物标志物的文献资料,评估他们的作用,以及他们的局限性,在早期诊断和预测一些肾脏疾病的临床结果。
关键词: 急性肾损伤(AKI)的新型生物标志物,肾,肾损伤分子(KIM-1)、中性粒细胞明胶酶相关脂质运载蛋白(NGAL)、白细胞介素-18(IL-18)、胱抑素C(Cys-C)。
Current Medicinal Chemistry
Title:Evaluation of Novel Biomarkers of Acute Kidney Injury: The Possibilities and Limitations
Volume: 23 Issue: 19
Author(s): Branislava Medić, Branislav Rovcanin, Katarina Savic Vujovic, Danilo Obradovic, Dusan Duric, Milica Prostran
Affiliation:
关键词: 急性肾损伤(AKI)的新型生物标志物,肾,肾损伤分子(KIM-1)、中性粒细胞明胶酶相关脂质运载蛋白(NGAL)、白细胞介素-18(IL-18)、胱抑素C(Cys-C)。
摘要: Despite the recent findings concerning pathogenesis and novel therapeutic strategies, the mortality rate in patients with acute kidney injury (AKI) remains very high. Early detection of patients with impaired renal function may help to ensure more aggresive treatment and to improve clinical outcome. Serum creatinine is still gold standard of kidney injury, although it is well known as an insensitive and unreliable biomarker (for example, its concentration does not increase significantly until about half of the kidney function is lost). Considering these data, researches and clinicians are making great efforts in the past decade in order to discover and validate novel AKI biomarkers. Kidney injury molecule-1 (KIM-1), Neutrophil gelatinase-associated lipocalin (NGAL), Interleukin-18 (IL-18), Cystatin C (Cys-C) are some of new, promising markers of kidney damage which are currently in the focus of preclinical and clinical studies. Recent data suggest that some of these new biomarkers represent important parametars of acute tubular necrosis (ATN) and reliable predictors of development and prognosis of AKI. Beside that, monitoring of these markers could have significant importance for early diagnosis and clinical course, not only in patients with various forms of AKI and other renal diseases, but also in patients with cardiorenal syndrome, heart failure, cardiopulmonary bypass, cardiothoracical surgical interventions, in the pediatric emergency setting etc.
The aim of this review is to summarize the literature data concerning some new biomarkers, evaluate their role as well as their limitations in the early diagnosis and predict clinical outcome of some renal diseases.
Export Options
About this article
Cite this article as:
Branislava Medić, Branislav Rovcanin, Katarina Savic Vujovic, Danilo Obradovic, Dusan Duric, Milica Prostran , Evaluation of Novel Biomarkers of Acute Kidney Injury: The Possibilities and Limitations, Current Medicinal Chemistry 2016; 23 (19) . https://dx.doi.org/10.2174/0929867323666160210130256
DOI https://dx.doi.org/10.2174/0929867323666160210130256 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Oral Anticoagulants in the Treatment of Acute Coronary Syndromes: Is there any Room for New Anticoagulants?
Current Clinical Pharmacology Treatment of Pulmonary Edema by ENaC Activators/Stimulators
Current Molecular Pharmacology NAD<sup>+</sup>/NADH Metabolism and NAD<sup>+</sup>-Dependent Enzymes in Cell Death and Ischemic Brain Injury: Current Advances and Therapeutic Implications
Current Medicinal Chemistry Transforming Growth Factor β Signaling Perturbation in the Loeys-Dietz Syndrome
Current Medicinal Chemistry mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets Interventions Against Sarcopenia in Older Persons
Current Pharmaceutical Design Current and Potential Anticancer Drugs Targeting Members of the UHRF1 Complex Including Epigenetic Modifiers
Recent Patents on Anti-Cancer Drug Discovery Dietary Phytoestrogens: Neuroprotective Role in Parkinson’s Disease
Current Neurovascular Research MicroRNAs and Peroxisome Proliferator-Activated Receptors Governing the Differentiation of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Individualizing Calcineurin Inhibitor Therapy in Renal Transplantation - Current Limitations and Perspectives
Current Pharmaceutical Design Congenital Malformations Attributed to Prenatal Exposure to Cyclophosphamide
Anti-Cancer Agents in Medicinal Chemistry How to Review the Medication History to Find the Next Best Drug: The “Pretreatment-Next Treatment Algorithm and Checklist”
Current Psychopharmacology The Heme Oxygenase/Biliverdin Reductase Pathway in Drug Research and Development
Current Drug Metabolism Editorial [Hot Topic: Paracrine Mechanisms, Signaling and Epigenetics in Repairing Damaged Tissue]
Recent Patents on Regenerative Medicine The Role of Renin Angiotensin System Blockade in the Treatment of Atrial Fibrillation
Current Drug Targets - Cardiovascular & Hematological Disorders The Relationship between Inflammatory and Oxidative Stress Biomarkers, Atherosclerosis and Rheumatic Diseases
Current Pharmaceutical Design Thrombotic Microangiopathy and Occult Neoplasia
Cardiovascular & Hematological Disorders-Drug Targets Assessment and Management of Volume Overload Among Patients on Chronic Dialysis
Current Vascular Pharmacology Antioxidant Therapy Against Trypanosome Infections: A Review Update
Current Topics in Medicinal Chemistry